Trial of Psilocybin versus Escitalopram for Depression
Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking.
Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking.
Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression.
Sub-anaesthetic doses of ketamine, a noncompetitive N-methyl-d-aspartate receptor antagonist provide rapid and long-lasting antidepressant effects in these patients, but the molecular mechanism of these effects remains unclear.